Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Limited information is currently available on TBX-3400, a putative a cell-based immunotherapy (Aug 2018).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TBX-3400||TBX-3400 is a recombinant fusion protein consisting of the HIV TAT protein transduction domain fused to the MYC protein and is used to treat patient autologous peripheral blood mononuclear cells to stimulate the immune system (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03385486||Phase I||TBX-3400||Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors||Recruiting|